Financial Reports Latest Updates Industry Maps Economic Calendar

Kura Oncology, Inc. (KURA) Annual Reports

Q: Where can I read Kura Oncology, Inc. (KURA) annual reports?

Every year on this page links straight to the full text on SEC EDGAR. US annual reports are web pages (HTML) rather than PDFs, so you can read and search them in the browser. 3 filings are currently indexed.

Q: What is the difference between a 10-K and a 20-F?

A 10-K is the annual report of a US domestic issuer; a 20-F is filed by foreign private issuers (Taiwanese companies with US ADRs, such as TSMC, file 20-F). A 40-F applies to Canadian issuers under the MJDS.

Kura Oncology, Inc. is listed on Nasdaq, classified by the SEC under Pharmaceutical Preparations (SIC 2834). This page indexes 3 annual reports, each linking to the full text on the SEC's EDGAR system.

Company profile

Exchange： Nasdaq
Fiscal year end： 12/31
SEC CIK： 1422143 →

Website：Official site ↗

Financial Highlights

FY2026 Q2 (quarterly, ended 2026-06-30)
	Current	Prior year	YoY
Revenue	$20.9M	$15.3M	+36.5%
Operating income	$-73.0M	$-72.7M	-0.5%
Net income	$-68.3M	$-66.1M	-3.3%
EPS (diluted)	$-0.77	$-0.75	-2.7%

Source: SEC EDGAR (XBRL company facts)

Financial history

Revenue & profit

Quarterly · In mn (USD)

Revenue 20.9 mn Net income -68.3 mn

Show table：Income statement

Item	2009Q4	2010Q2	2010Q3	2010Q4	2011Q3	2011Q4	2011Q4	2011Q4	2012Q4	2012Q4	2012Q4	2012Q4	2013Q4	2013Q4	2013Q4	2013Q4	2014Q4	2014Q4	2014Q4	2014Q4	2015Q1	2015Q2	2015Q3	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
Revenue	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	0	—	—	—	53.9	14.1	15.3	20.8	17.3	18.3	20.9
Operating income	—	-0.01	0	-0.01	0	-0.01	-0.01	-0.01	0	0	0	-0.01	0	-0.01	0	-0.01	0	-0.01	0	-0.01	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	-140	—	—	—	-166	-54.5	-56.4	-59.9	-22.4	-64.7	-72.7	-80.0	-86.3	-78.8	-73.0
Net income	-0.02	-0.01	0	-0.01	-0.01	-0.01	-0.01	-0.01	-0.01	-0.01	-0.01	-0.01	-0.01	-0.01	-0.01	-0.01	-0.01	-0.01	-0.07	-3.60	-4.48	-5.58	-6.09	-6.47	-6.63	-6.66	-6.93	-7.35	-7.53	-7.82	-9.33	-10.8	-14.6	-14.7	-15.0	-16.1	-13.9	-14.9	-16.4	-17.9	-19.2	-20.5	-23.8	-26.2	-30.7	-33.7	-33.4	-32.7	-32.5	-34.8	-35.5	-33.1	-34.1	-37.2	-38.6	-42.8	-49.5	-50.8	-54.4	-19.2	-57.4	-66.1	-74.1	-81.0	-73.3	-68.3

Balance sheet

Quarterly · In mn (USD)

Total assets 588 mn Total liabilities 539 mn

Equity = assets − liabilities. Balance-sheet figures are period-end balances, not cumulative.

Show table：Balance sheet

Item	2009Q4	2010Q2	2010Q3	2010Q4	2011Q3	2011Q4	2011Q4	2011Q4	2012Q4	2012Q4	2012Q4	2012Q4	2013Q4	2013Q4	2013Q4	2013Q4	2014Q4	2014Q4	2014Q4	2014Q4	2015Q1	2015Q2	2015Q3	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
Current assets	—	—	—	0.03	0.01	0.02	0.01	0.01	0.02	0.02	0.01	0.01	0	—	—	—	—	—	—	1.20	54.6	47.2	42.3	86.9	80.1	81.4	75.7	68.8	60.6	54.7	102	94.6	140	129	190	181	168	264	253	240	221	342	329	637	611	574	549	522	487	460	436	446	416	486	460	432	538	500	463	745	724	660	621	709	624	559
Total assets	—	—	—	—	—	—	—	—	—	—	—	0.01	—	0.02	0.01	0.01	0.01	0	0.02	0.01	54.8	47.5	42.8	87.3	80.4	81.7	76.3	69.8	61.9	55.9	103	95.8	141	130	192	182	170	266	255	242	226	353	340	647	620	585	561	534	499	471	448	456	426	495	474	449	554	515	479	760	744	682	649	738	653	588
Current liabilities	—	—	—	0.07	0.07	0.07	0.07	0.07	0.1	0.1	0.1	0.1	0.11	—	—	—	—	—	—	3.02	5.53	3.60	4.71	5.06	4.31	4.38	5.27	5.45	4.12	5.08	7.56	10.0	11.3	12.6	12.9	13.6	12.1	11.2	13.1	15.6	14.6	18.6	21.7	26.0	25.1	21.3	21.9	22.5	17.7	17.9	24.8	24.1	19.2	23.9	27.5	35.3	32.3	33.5	40.4	78.7	89.8	107	121	117	102	118
Total liabilities	—	—	—	—	—	—	—	—	—	—	—	0.1	—	0.13	0.13	0.13	0.14	0.14	0.16	0.16	5.92	4.21	5.04	5.16	4.32	11.7	12.6	12.9	11.7	12.2	13.9	16.0	16.7	17.2	16.9	21.4	20.1	19.1	21.0	23.2	23.3	30.6	33.1	36.3	34.3	26.3	27.4	27.4	22.3	21.9	28.4	36.0	30.8	35.1	43.8	51.7	48.8	49.0	55.1	347	379	377	407	564	545	539
Equity	-0.02	—	—	-0.04	-0.07	-0.05	-0.06	-0.07	-0.07	-0.08	-0.09	-0.1	-0.1	-0.11	-0.11	-0.12	-0.13	-0.14	-0.14	-0.15	48.9	43.3	37.8	82.1	76.1	70.0	63.7	56.9	50.2	43.6	89.2	79.9	125	112	175	161	150	247	234	219	203	322	307	611	586	559	534	507	476	449	420	420	395	460	430	397	505	466	424	414	364	305	243	174	108	48.4

Cash flow

Quarterly · In mn (USD)

Operating -62.5 mn Investing 92.2 mn Financing 1.50 mn

Positive = cash in, negative = cash out.

Show table：Cash flow statement

Item	2009Q4	2010Q2	2010Q3	2010Q4	2011Q3	2011Q4	2011Q4	2011Q4	2012Q4	2012Q4	2012Q4	2012Q4	2013Q4	2013Q4	2013Q4	2013Q4	2014Q4	2014Q4	2014Q4	2014Q4	2015Q1	2015Q2	2015Q3	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
Operating	—	-0.02	0	0	0	-0.02	0	0	-0.01	-0.01	0	0	0	-0.01	-0.01	0	0	0	-0.02	-0.83	-4.12	-3.77	-4.43	-5.60	-7.31	-5.82	-5.47	-6.74	-8.62	-6.11	-6.23	-7.47	-12.8	-12.6	-13.0	-10.2	-14.3	-14.4	-12.1	-13.9	-19.8	-14.7	-17.0	-18.3	-28.5	-28.1	-24.6	-23.4	-32.2	-30.3	-21.0	-26.5	-35.9	-25.6	-29.0	-34.3	-48.8	-42.5	-43.4	269	-71.9	-28.8	-80.6	117	-85.8	-62.5
Investing	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	-0.01	-0.02	-0.01	-26.3	-3.89	-40.5	8.20	-5.84	0.14	9.68	9.53	7.43	-36.3	-4.09	-29.7	3.86	-58.1	4.62	15.8	8.88	-55.8	-15.3	27.5	-21.7	-45.5	-60.2	-186	-37.2	22.6	74.1	-25.0	33.1	71.8	-47.3	11.1	-46.3	8.56	42.2	-95.3	43.2	45.5	-95.0	-101	58.9	94.0	-64.6	-24.2	92.2
Financing	—	0.01	0	0.03	0	0	0	0	0.03	0	0	0	0	0.03	0	0	0	0	0.11	1.89	56.6	-3.74	-0.25	50.3	—	7.45	0	0	0.01	0.19	53.7	-0.34	57.6	-0.12	74.0	1.14	0.1	110	0.56	0.58	0.25	137	4.68	327	0.08	-6.57	2.26	0.79	0.3	2.67	0.88	34.7	—	94.0	0.08	0.69	148	3.04	2.20	0.81	0.14	0.52	0	1.14	0.07	1.50
Cash at period end	0.01	0.01	0	0.03	0	0.01	0.01	0	0.02	0.01	0.01	0	0	0.02	0.01	0.01	0.01	0	0.02	0.01	53.6	19.8	11.2	15.4	16.3	12.1	6.78	9.73	10.6	12.2	23.3	11.4	26.5	17.7	20.6	16.1	17.8	122	54.7	26.1	33.8	135	77.0	325	111	39.0	39.2	90.7	33.8	39.3	90.9	51.8	27.1	49.1	28.7	37.3	41.5	45.2	49.5	224	51.3	82.0	95.3	149	39.1	70.2

Profitability

Quarterly · %

Operating margin -349.8% Net margin -327.3%

Gross, operating and net margin = the respective profit ÷ revenue.

Show table：Profitability

Item	2009Q4	2010Q2	2010Q3	2010Q4	2011Q3	2011Q4	2011Q4	2011Q4	2012Q4	2012Q4	2012Q4	2012Q4	2013Q4	2013Q4	2013Q4	2013Q4	2014Q4	2014Q4	2014Q4	2014Q4	2015Q1	2015Q2	2015Q3	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
Operating margin	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	-41.7%	-458.6%	-475.3%	-385.5%	-497.6%	-431.5%	-349.8%
Net margin	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	-35.7%	-407.1%	-432.5%	-357.2%	-467.2%	-401.5%	-327.3%

Returns & leverage

Quarterly · %

ROE -167.7% ROA -46.7% Debt ratio 91.8%

ROE / ROA = trailing four-quarter net income ÷ average equity / total assets (annual mode: the year’s net income ÷ average of opening and closing). Not computed when the denominator is zero or negative.

Show table：Returns & leverage

Item	2009Q4	2010Q2	2010Q3	2010Q4	2011Q3	2011Q4	2011Q4	2011Q4	2012Q4	2012Q4	2012Q4	2012Q4	2013Q4	2013Q4	2013Q4	2013Q4	2014Q4	2014Q4	2014Q4	2014Q4	2015Q1	2015Q2	2015Q3	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
ROE	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	-33.4%	-63.6%	-105.0%	-55.2%	-39.6%	-45.6%	-52.6%	-39.7%	-45.1%	-52.1%	-41.9%	-51.8%	-48.6%	-63.4%	-41.8%	-50.2%	-43.6%	-33.4%	-30.1%	-33.3%	-38.8%	-26.0%	-30.1%	-21.6%	-25.6%	-25.9%	-29.5%	-23.4%	-24.9%	-26.4%	-28.4%	-29.3%	-31.6%	-30.8%	-33.6%	-37.3%	-37.3%	-39.3%	-46.3%	-42.9%	-41.8%	-51.1%	-65.1%	-94.8%	-124.7%	-167.7%
ROA	—	—	—	—	—	—	—	—	—	—	—	-329.0%	—	-151.8%	-190.7%	-329.4%	-418.1%	-241.7%	-533.0%	-50182.6%	-29.8%	-57.8%	-92.2%	-51.9%	-36.6%	-40.0%	-44.8%	-35.1%	-40.0%	-43.1%	-35.7%	-42.8%	-41.8%	-53.3%	-37.4%	-43.5%	-38.4%	-30.4%	-27.5%	-29.8%	-34.5%	-23.9%	-27.4%	-20.2%	-23.9%	-24.4%	-27.5%	-22.1%	-23.6%	-25.2%	-26.9%	-27.4%	-29.7%	-28.9%	-31.0%	-33.7%	-34.3%	-36.0%	-41.5%	-28.8%	-28.0%	-32.9%	-38.5%	-37.2%	-42.2%	-46.7%
Debt ratio	—	—	—	—	—	—	—	—	—	—	—	1248.5%	—	677.8%	863.7%	1467.0%	2009.7%	2877.8%	885.2%	2855.9%	10.8%	8.8%	11.8%	5.9%	5.4%	14.3%	16.6%	18.5%	18.9%	21.9%	13.5%	16.7%	11.8%	13.3%	8.8%	11.7%	11.8%	7.2%	8.3%	9.6%	10.3%	8.7%	9.7%	5.6%	5.5%	4.5%	4.9%	5.1%	4.5%	4.7%	6.3%	7.9%	7.2%	7.1%	9.3%	11.5%	8.8%	9.5%	11.5%	45.6%	51.0%	55.2%	62.6%	76.4%	83.5%	91.8%

EPS

Quarterly · US$

EPS US$-0.77

Show table：EPS

Item	2009Q4	2010Q2	2010Q3	2010Q4	2011Q3	2011Q4	2011Q4	2011Q4	2012Q4	2012Q4	2012Q4	2012Q4	2013Q4	2013Q4	2013Q4	2013Q4	2014Q4	2014Q4	2014Q4	2014Q4	2015Q1	2015Q2	2015Q3	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
EPS（US$）	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	-1.69	—	-0.51	-0.50	-0.50	-0.49	-0.52	-0.53	-0.49	-0.50	-0.53	-0.50	-0.55	-0.59	-0.59	-0.63	-0.22	-0.66	-0.75	-0.85	-0.92	-0.83	-0.77

Revenue & profit

Year-to-date · In mn (USD)

Revenue 39.1 mn Net income -142 mn

Year-to-date = summed from the first quarter of the fiscal year; balance-sheet items are period-end balances.

Balance sheet

Year-to-date · In mn (USD)

Total assets 588 mn Total liabilities 539 mn

Equity = assets − liabilities. Balance-sheet figures are period-end balances, not cumulative.

Cash flow

Year-to-date · In mn (USD)

Operating -148 mn Investing 68.0 mn Financing 1.57 mn

Positive = cash in, negative = cash out.

Profitability

Year-to-date · %

Operating margin -387.9% Net margin -361.9%

Gross, operating and net margin = the respective profit ÷ revenue.

Returns & leverage

Year-to-date · %

ROE -167.7% ROA -46.7% Debt ratio 91.8%

EPS

Year-to-date · US$

EPS US$-1.60

Revenue & profit

Annual · In mn (USD)

Revenue 67.5 mn Net income -279 mn

Annual = sum of four quarters of a complete fiscal year (incomplete years are omitted); balance-sheet items are year-end balances.

Show table：Income statement

Item	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Revenue	—	—	—	—	—	—	—	—	—	—	67.5
Operating income	—	—	—	—	—	—	—	—	—	-193	-304
Net income	-22.6	-27.6	-35.4	-60.5	-63.1	-89.6	-130	-136	-153	-174	-279

Balance sheet

Annual · In mn (USD)

Total assets 738 mn Total liabilities 564 mn

Equity = assets − liabilities. Balance-sheet figures are period-end balances, not cumulative.

Show table：Balance sheet

Item	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Current assets	86.9	68.8	94.6	181	240	637	522	446	432	745	709
Total assets	87.3	69.8	95.8	182	242	647	534	456	449	760	738
Current liabilities	5.06	5.45	10.0	13.6	15.6	26.0	22.5	24.1	35.3	78.7	117
Total liabilities	5.16	12.9	16.0	21.4	23.2	36.3	27.4	36.0	51.7	347	564
Equity	82.1	56.9	79.9	161	219	611	507	420	397	414	174

Cash flow

Annual · In mn (USD)

Operating -64.1 mn Investing -13.1 mn Financing 1.79 mn

Positive = cash in, negative = cash out.

Show table：Cash flow statement

Item	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Operating	-17.9	-25.4	-28.4	-48.6	-54.8	-69.8	-105	-110	-125	134	-64.1
Investing	-70.6	12.2	-23.4	-79.3	-46.3	-99.9	-127	32.6	15.6	-102	-13.1
Financing	103	—	53.6	133	111	469	-3.43	38.6	—	154	1.79
Cash at period end	15.4	9.73	11.4	16.1	26.1	325	90.7	51.8	37.3	224	149

Profitability

Annual · %

Operating margin -449.9% Net margin -412.9%

Gross, operating and net margin = the respective profit ÷ revenue.

Show table：Profitability

Item	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Operating margin	—	—	—	—	—	—	—	—	—	—	-449.9%
Net margin	—	—	—	—	—	—	—	—	—	—	-412.9%

Returns & leverage

Annual · %

ROE -94.8% ROA -37.2% Debt ratio 76.4%

Show table：Returns & leverage

Item	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
ROE	-27.6%	-39.7%	-51.8%	-50.2%	-33.3%	-21.6%	-23.4%	-29.3%	-37.3%	-42.9%	-94.8%
ROA	-25.9%	-35.1%	-42.8%	-43.5%	-29.8%	-20.2%	-22.1%	-27.4%	-33.7%	-28.8%	-37.2%
Debt ratio	5.9%	18.5%	16.7%	11.7%	9.6%	5.6%	5.1%	7.9%	11.5%	45.6%	76.4%

EPS

Annual · US$

EPS US$-3.18

Show table：EPS

Item	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
EPS（US$）	—	—	—	—	—	—	—	-2.03	-2.08	-2.03	-3.18

Source: SEC EDGAR (XBRL company facts)

Annual reports by year

	10-K
2025	Open full text →
2024	Open full text →
2023	Open full text →

10-K: annual report of a US domestic issuer. Filings are the original documents hosted on SEC EDGAR — this site neither mirrors nor edits them.

FAQ

Where can I read Kura Oncology, Inc. (KURA) annual reports?

Every year in the table above links straight to the full text on SEC EDGAR. US annual reports are web pages (HTML) rather than PDFs, so you can read and search them in the browser without downloading anything. 3 filings are currently indexed.

What is the difference between a 10-K and a 20-F?

A 10-K is the annual report of a US domestic issuer, with sections fixed by law: Item 1 Business, Item 1A Risk Factors, Item 7 Management's Discussion and Analysis. A 20-F is filed by foreign private issuers — Taiwanese companies with US ADRs, such as TSMC, file 20-F rather than 10-K. A 40-F applies to Canadian issuers under the MJDS.

Are earnings call materials available here?

No. Earnings calls are not SEC filings, so US pages on this site cover annual reports only. Taiwan has a mandatory investor-conference disclosure regime, and those materials are indexed under Annual Reports.

Source: US Securities and Exchange Commission (SEC) EDGAR. This site indexes public filings and links to them; it hosts no copies, offers no investment advice, and makes no warranty as to timeliness or completeness.
Back to US annual reports, or see the supply-chain maps.